Takayasu Y, Kumada T, Ito K
Dept. of Radiology, Hyogo College of Medicine.
Gan To Kagaku Ryoho. 1999 Aug;26(9):1283-8.
We had the opportunity to use "Vital Port", a subcutaneous implantable vascular access port which was developed in the U.S. and has been used clinically in a multicenter study for clinical evaluation. To prevent the result from varying by facility, standardized criteria were made. The access port was implanted in 31 patients, and then intra-arterial infusion chemotherapy was performed. The follow-up period was 4 weeks. No complications were observed in any of the cases. Intra-arterial infusion chemotherapy was carried out without any problem. This port is lightweight and has good biocompatibility, and the clinical results were evaluated highly.
我们有机会使用“Vital Port”，这是一种在美国研发的皮下植入式血管通路端口，已在一项多中心临床研究中用于临床评估。为防止结果因机构不同而有所差异，制定了标准化标准。该通路端口植入了31例患者体内，随后进行了动脉内灌注化疗。随访期为4周。所有病例均未观察到并发症。动脉内灌注化疗进行得毫无问题。这个端口重量轻，生物相容性好，临床结果得到了高度评价。
